The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

As the controlling shareholder of Novo Nordisk, a leading Danish pharmaceutical company, the takeover emerges amidst rising ...

Studies also show that incretin-based therapies like Wegovy and Mounjaro are much less effective ... In 2023, Embark Biotech was acquired by Novo Nordisk to develop next generation therapeutics for ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

In the case of popular medications like Ozempic and Wegovy, the drug manufacturer Novo Nordisk told Global News the company has mitigation plans to minimize any disruption.

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...